Toll Free: 1-888-928-9744

Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Review, H1 2016', provides in depth analysis on Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Overview 6 Therapeutics Development 7 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Stage of Development 7 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Therapy Area 8 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Indication 9 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Companies 12 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Universities/Institutes 14 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Companies Involved in Therapeutics Development 21 Astex Pharmaceuticals, Inc. 21 Presage Biosciences, Inc. 22 Tiziana Life Sciences Plc 23 Tragara Pharmaceuticals, Inc. 24 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Drug Profiles 25 AT-7519 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 milciclib - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 TG-02 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 voruciclib - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Dormant Projects 36 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Discontinued Products 38 Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Featured News & Press Releases 39 Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors 39 Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer 39 Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 40 May 28, 2014: Tragara's TG02 is Highly Active in CLL Cells Derived from Patients who have Failed Treatment with Ibrutinib 41 May 14, 2014: Phase II data of Nerviano Medical Science's kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 42 Apr 07, 2014: New Preclinical Data of Tragara's TG02 in Acute Leukemia at AACR Meeting in San Diego 42 Dec 06, 2013: New Preclinical Data of Tragara's TG02 in Multiple Myeloma and Leukemia to be Presented at ASH 2013 Annual Meeting 43 Dec 03, 2013: Tragara Initiates Clinical Study of TG02 in Combination with Carfilzomib in Multiple Myeloma 43 Sep 12, 2013: Tragara Announces Oral Presentation at Society of Hematology Oncology Annual Meeting 44 May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02 44 May 22, 2012: Piramal Healthcare To Present Phase I Data For New Oral Anticancer Molecule At ASCO Annual Meeting 45 Apr 03, 2012: Piramal Healthcare To Present Preclinical Data On Tumor Drug P1446A-05 At 2012 AACR Annual Meeting 47 Apr 02, 2012: Tragara Pharma Announces Presentation Of Preclinical Data Of TG02 At 2012 AACR Annual Meeting 47 Sep 14, 2011: Tragara And Multiple Myeloma Research Foundation Initiate Phase I Clinical Study Of TG02 In Multiple Myeloma Patients 48 Mar 23, 2011: Tragara To Present TG02 Poster At 102nd AACR Annual Meeting 49 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Astex Pharmaceuticals, Inc., H1 2016 21 Pipeline by Presage Biosciences, Inc., H1 2016 22 Pipeline by Tiziana Life Sciences Plc, H1 2016 23 Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 24 Dormant Projects, H1 2016 36 Dormant Projects (Contd..1), H1 2016 37 Discontinued Products, H1 2016 38



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify